Financial StabilityIterum expects to have runway into 2026, providing financial stability for ongoing operations.
Product ApprovalOrlynvah is the first oral penem approved in the US for uncomplicated urinary tract infections, adding unique value to the market.
Treatment EfficacyThe FDA-approved label for Orlynvah covers over 95% of microbes associated with uUTIs, providing a comprehensive treatment option.